Top Markets
#1 Black Phoenix Black Phoenix +354.09%
#2 Akedo Akedo +105.75%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +58.06%
#5 Acurast Acurast +40.10%
#6 OpenEden OpenEden +39.66%
#7 BasedHype BasedHype +27.11%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.53%
#9 Cryptopia Cryptopia +21.54%
#10 Bedrock Bedrock +19.76%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Endo International plc Endo International plc

Endo International plc

0Y5F
Rangering i aksjer #40684
Endo International plc is a specialty pharmaceutical company that develops,... Endo International plc is a specialty pharmaceutical company that develops, manufactures, and markets both branded and generic medications across the United States and globally. Its operations are divided into several key segments: Branded Pharmaceuticals: This division offers a portfolio of signature prescription medications, addressing conditions such as Dupuytren's contracture (XIAFLEX), central precocious puberty (SUPPRELIN LA), vitamin B12 deficiency (NASCOBAL), hypogonadism (AVEED), and moderate-to-severe cellulite (QWO). It also includes treatments for moderate to moderately severe pain (PERCOCET), testosterone replacement therapy (TESTOPEL), erectile dysfunction (EDEX), and pain relief with topical patches (LIDODERM), among other pain management and urology products. Sterile Injectables: This segment is responsible for producing essential branded formulations like VASOSTRICT (a vasopressin injection) and ADRENALIN (an adrenergic agonist), as well as APLISOL, a sterile aqueous solution. It also develops and supplies various generic sterile injectable products, including ertapenem and ephedrine sulfate injections. Generic Pharmaceuticals: This segment encompasses a wide array of generic drug formulations, spanning various delivery methods including solid oral extended and immediate-release forms, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. International Pharmaceuticals: Operating globally, this segment provides specialized pharmaceutical products across diverse therapeutic categories such as attention deficit hyperactivity disorder (ADHD), pain management, women's health, oncology, and transplantation. Endo distributes its branded and generic products through a broad network of channels, reaching specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialized distributors. The company was established in 1920 and maintains its headquarters in Dublin, Ireland. A significant recent development occurred on August 16, 2022, when Endo International plc, along with its affiliated entities, initiated bankruptcy proceedings by filing a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Aksjekurs
$0.0006
Sist synkronisert: 2024-04-24
Markedsverdi
$98.97K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
IE
Handel Endo International plc (0Y5F)

Kategori

Healthcare
P/E-forhold for Endo International plc (0Y5F)
P/E-forhold per 2026 TTM: 0
Ifølge Endo International plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Endo International plc fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 23.71 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 220.17 -
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.